Neoplasms, Connective and Soft Tissue
11
3
3
1
Key Insights
Highlights
Success Rate
25% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 65/100
27.3%
3 terminated out of 11 trials
25.0%
-61.5% vs benchmark
18%
2 trials in Phase 3/4
200%
2 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (11)
An Electronic Health Record (EHR)-Based Comprehensive Bone and Soft Tissue Tumor Registry
A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
Neoadjuvant Combination of Doxorubicin, Cisplatin and Methotrexate in Patients Aged 24-40 Years With Primary Bone Tumors
Percutaneous Needle Fasciotomy +/- Corticosteroid Injection for Dupuytren's Contracture
A Trial For Participants With Ewing's Sarcoma Treated With Vigil in Combination With Irinotecan and Temozolomide
Effect of Negative Pressure Wound Therapy After Surgical Removal of Deep-Seated High-Malignant Soft Tissue Sarcomas of the Extremities and Trunk Wall.
Camrelizumab Plus Doxorubicin for the First Line Treatment of Adcanced Soft Tissue Sarcoma
Autologous Dendritic Cell Vaccine in Patients With Soft Tissue Sarcoma
Eltrombopag for the Prevention of Chemotherapy Induced Thrombocytopenia
A Safety Study Utilizing Yondelis and Doxorubicin in Patients With a Type of Cancer Called Soft Tissue Sarcoma
Study of Vinorelbine and Cyclofosfamide Among Patients With Refractory Tumours or in Relapse